Described are rapid and highly efficient procedures for the total synthesis of linear, double stranded DNA sequences in excess of about 200 base pairs in length, which sequences may comprise entire structural genes. Novel sequences are prepared from two or more DNA subunits provided with terminal regions comprising restriction endonuclease cleavage sites facilitating insertion of subunits into a selected vector for purposes of amplification during the course of the total assembly process. The total, finally-assembled assembled sequences include at least one, and preferably two or more, unique restriction endonuclease cleavage site(s) at intermediate positions along the sequence, allowing for easy excision and replacement of subunits and the correspondingly facile preparation of multiple structural analogs of polypeptides coded for by the sequences. Manufactured genes preferably include codons selected from among alternative codons specifying the same amino acid on the basis of preferential expression in a projected host microorganism (e.g., E. coli) to be transformed. Illustrated is the preparation and expression of manufactured genes capable of directing synthesis of human immune and leukocyte interferons and of other biologically active proteinaceous products, which products differ from naturally-occurring forms in terms of the identity and/or relative position of one or more amino acids, and in terms of one or more biological and pharmacological properties but which substantially retain other such properties.
This is a division of U.S. patent application Ser. No. 483,451 filed Apr. 15, 1983 continuation-in-part of co-pending U.S. patent application Ser. No. 375,494, filed May 6, 1982.
USPTO Field of Search
260/112R
260/112.5R
435/172.3
435/68
530/351
Related Patents
5541293 - Consensus human leukocyte interferon - Owned by Amgen Inc. (Thousand Oaks, CA) [*] Notice:The portion of the term of this patent subsequent to September 22, 2004 has been disclaimed.
Disclosed are analogs of human leukocyte interferon which predominantly include those amino acid residues which are common to all naturally-occurring human leukocyte interferon subtype amino acid sequences and which include, at one or more of those positions where there is no amino acid common to all subtypes, an amino acid which predominantly occurs at that position and in no event include any amino acid residue which is not extant in that position in at least one naturally-occurring subtype.
Methods for the treatment of cell proliferation disorders, viral infections, and other conditions without causing significant side effects normally associated with interferon therapy, involving administering to a patient in need thereof a therapeutically effective amount of consensus human leukocyte interferon are disclosed. Also disclosed are pharmaceutical compositions of consensus human leukocyte interferon.
Synthetic human interleukin-1.alpha. genes are provided whose codons are selected from those preferred by bacteria. High expression levels are obtained in an E. coli expression system for both native interleukin-1.alpha. and several mutant interleukin-1.alpha.'s.
6843988 - Synferon - Owned by Human Genome Sciences, Inc. (Rockville, MD)
The present invention relates to a novel Synferon protein which is a member of the interferon family. In particular, isolated nucleic acid molecules are provided encoding a synthetic interferon polypeptide, called "Synferon". Synferon polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of Synferon activity. Also provided are therapeutic methods for treating immune system-related disorders.
A structural gene coding for authentic human serum albumin, --optionally supplemented by an upstream triplet coding for methionine and optionally extended by a synthetic prepro.sup.x -leader-coding sequence--, wherein the codons of the nucleotide sequence have been selected with regard to a non-human host, e.g. yeast, chosen for expression of authentic human serum albumin, is disclosed. Additionally there is disclosed a method of producing said gene. There are also disclosed a recombinant DNA molecule comprising said strucural gene inserted into a vector, and a host transformed with said recombinant DNA molecule. Furthermore there are disclosed a method of producing authentic human serum albumin, an authentic human serum albumin resulting from said method, and a pharmaceutical composition comprising said resulting human serum albumin.
